)
Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company, has received two product patents from Europe corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases. These patents are valid through 2023 and 2029.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and being developed as therapeutic agents. These are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s, Parkinson and Schizophrenia, the company informed the exchanges on Thursday.
